ds-1040b
Small moleculeexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2014 (NCT02071004)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Carboxypeptidase B2 isoform AINHIBITOR
CPB2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ds-1040b
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03198715 | N/A | Jul 30, 2017 | Daiichi Sankyo |
| NCT02923115 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2016 | Daiichi Sankyo, Medpace, Inc. |
| NCT02647307 | Phase 1 | Feb 1, 2016 | Daiichi Sankyo, Hammersmith Medicines Research |
| NCT02560688 | Phase 1 | Dec 1, 2015 | Daiichi Sankyo |
| NCT02586233 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2015 | Daiichi Sankyo |
| NCT02071004 | Phase 1 | Jan 1, 2014 | Daiichi Sankyo |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Daiichi Sankyo | For profit | 6 | 6 | 3 | 2014 |
| Hammersmith Medicines Research | For profit | 1 | 0 | 1 | 2016 |
| Medpace, Inc. | For profit | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1